Table 8. Cellular immune responses against Candida after Tat immunization.
| ISS T-002 | Tat 7.5 µgb | Tat 30 µgc | ||||
| n | Baseline | Up to week 48 | n | Baseline | Up to week 48 | |
| IFN-γ | ||||||
| Peaka (SFC/106 cells) | 6 | 40 (0–70) | 69 (46–150) | 5 | 82 (82–118) | 132 (82–266) |
| IL-2 | ||||||
| Peaka (SFC/106 cells) | 28 | 98 (28–181) | 175 (101–346)** | 28 | 73 (48–111) | 133 (93–259)** |
| IL-4 | ||||||
| Peaka (SFC/106 cells) | 13 | 8 (0–34) | 66 (36–124)** | 16 | 6 (0–13) | 60 (34–110)** |
| CD4 Proliferation | ||||||
| Peaka (fold increase) | 20 | 1.6 (1.2–2.0) | 4.8 (2.3–6.1)** | 24 | 1.7 (1.2–2.8) | 4.1 (2.8–4.9)** |
| CD8 Proliferation | ||||||
| Peaka (fold increase) | 19 | 1.8 (1.3–4.6) | 4.9 (2.8–9.9)** | 19 | 1.5 (1.2–3.8) | 5.7 (3.9–8.9)** |
IFN-γ, IL-2, IL-4 production by PBMC, and CD4 or CD8 lymphoproliferative responses to Candida were measured at baseline and up to week 48 after the first immunization, respectively. Results are stratified by Tat doses, (7.5 and 30 µg). n indicates the number of responders for cytokines production and CD4 or CD8 T cell proliferation, respectively. The median intensity with interquartile range of peak of responses is shown. Pre-post vaccination median change was evaluated by Wilcoxon signed-rank test.
a
Median (interquartile range) of peak of responses, weeks 8, 12, 20, 48.
b
Total subject tested for cytokines: 32; for proliferation: 29.
c
Total subjects tested for cytokines: 29; for proliferation: 29.
**P<0.05, ** P<0.01.